(Q34810768)

4 August 2017

1 reference

title

On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer (English)

1 reference

4 August 2017

0 references

1 reference

Cornelius J McGinn

1

1 reference

4 August 2017

Theodore S Lawrence

series ordinal

2

1 reference

4 August 2017

Mark M Zalupski

series ordinal

3

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

4 August 2017

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

4 August 2017

95

1 reference

4 August 2017

4 Suppl

1 reference

4 August 2017

933-940

1 reference

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

4 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

The effect of 2'-2' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

Radiosensitizing nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrop

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

The clinical application of a non-axial treatment plan for pancreatic and biliary malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

7 January 2021

Maximizing therapeutic gain with gemcitabine and fractionated radiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

7 January 2021

Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

7 January 2021

Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

7 January 2021

Three-dimensional conformal pancreas treatment: comparison of four- to six-field techniques

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

7 January 2021

Recent advances in radiation oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10754

7 January 2021

Identifiers

DOI

10.1002/CNCR.10754

1 reference

4 August 2017

1 reference